Gut microbiota diets enhance anti-diabetic medication reveals study

New Delhi: A clinical trial conducted in India has unveiled promising findings regarding the management of diabetes through personalized gut microbiota-directed diets.

Utilizing BugSpeaks, a pioneering technology developed by Leucine Rich Bio, the study demonstrated remarkable improvements in diabetic patients’ health markers after three months of personalized dietary interventions.

The trial, comprising 30 Indian adults aged 42-65 with hyperglycemia and hyperlipidemia, divided participants into two groups: one receiving personalized diets based on BugSpeaks recommendations and the other adhering to regular dietary patterns. Upon evaluation on day 90, individuals following the BugSpeaks-based diet exhibited significant enhancements across various parameters.

Notably, participants experienced a substantial reduction in average HbA1c levels, dropping from 8.30 to 6.67, indicative of improved blood sugar control. Additionally, systolic blood pressure decreased by 14%, and CRP levels, a marker of inflammation, decreased by 20%. These findings underscore the potential of personalized gut microbiota-based nutritional modulation in complementing traditional anti-diabetic medication for enhanced disease management, particularly in the context of type 2 diabetes

Dr. Debojyoti Dhar, Co-founder & Director of Business Development and Innovation at Leucine Rich Bio, and the lead author of the study stated, “In this study, we have highlighted the positive effect of gut microbiota-based personalized nutrition on hyperglycaemia, hypertension, and inflammation markers. This “proof of concept” clinical trial shows that BugSpeaks based nutritional modulation of the gut microbiota can impact the health positively and can supplement medication for diseases like type 2 diabetes.”

He added, “We plan to conduct more such trials in the coming months for other diseases for which we have anecdotal evidence. Gut microbiota modulation through nutrition can provide a new dimension in the precision or personalized healthcare paradigm and this study is a step towards that direction.”

The study also shed light on the beneficial alterations in gut microbiota composition induced by personalized diets. Beneficial microorganisms such as Phascolarctobacterium succinatutens and Bifidobacterium angulatum exhibited a two-fold increase, while non-beneficial species like Alistipes finegoldii decreased significantly. This underscores the critical role of maintaining gut microbiota balance, as dysbiosis can contribute to various health issues beyond diabetes management.